Pneumoconiosis secondary prevention

Jump to navigation Jump to search

Pneumoconiosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pneumoconiosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pneumoconiosis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pneumoconiosis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pneumoconiosis secondary prevention

CDC on Pneumoconiosis secondary prevention

Pneumoconiosis secondary prevention in the news

Blogs on Pneumoconiosis secondary prevention

Directions to Hospitals Treating Pneumoconiosis

Risk calculators and risk factors for Pneumoconiosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dushka Riaz, MD

Overview

Effective measures for the secondary prevention of pneumoconiosis include avoiding further exposure and being vaccinated. [1]

Secondary Prevention

Effective measures for the secondary prevention of pneumoconiosis include: [2] [3] [4] [5]

References

  1. Cullinan P, Reid P (2013). "Pneumoconiosis". Prim Care Respir J. 22 (2): 249–52. doi:10.4104/pcrj.2013.00055. PMC 6442808. PMID 23708110.
  2. Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Cragle DL; et al. (2011). "Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry". Occup Environ Med. 68 (11): 842–8. doi:10.1136/oem.2010.064220. PMC 4347849. PMID 21460389.
  3. Sood A (2009). "Current treatment of chronic beryllium disease". J Occup Environ Hyg. 6 (12): 762–5. doi:10.1080/15459620903158698. PMC 2774897. PMID 19894178.
  4. "IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Silica, Some Silicates, Coal Dust and Para-Aramid Fibrils. Lyon, 15-22 October 1996". IARC Monogr Eval Carcinog Risks Hum. 68: 1–475. 1997. PMC 5366849. PMID 9303953.
  5. Pelucchi C, Pira E, Piolatto G, Coggiola M, Carta P, La Vecchia C (2006). "Occupational silica exposure and lung cancer risk: a review of epidemiological studies 1996-2005". Ann Oncol. 17 (7): 1039–50. doi:10.1093/annonc/mdj125. PMID 16403810.

Template:WH Template:WS